Dennis Wright, Ph.D.

Professor of Medicinal Chemistry University of Connecticut

  • Storrs CT

Prof. Dennis Wright is an expert in medicinal pharmacy, therapeutic development for infectious disease and cancer.

Contact

University of Connecticut

View more experts managed by University of Connecticut

Biography

Dennis Wright, professor of medicinal pharmacy. Therapeutic development for infectious disease and cancer. Wright has recently improved upon a new way to thwart the pathogen Tuberculosis (TB) which has become difficult to fight because antibiotics that have been used to cure the old and notoriously difficult to treat disease, are becoming less and less effective.

Areas of Expertise

Drug Design
Infectious Disease
Cancer
Medicinal Chemistry

Education

Ohio University

Ph.D.

Chemistry

West Liberty State College

B.S.

Chemistry

Media

Articles

The furan route to tropolones: probing the antiproliferative effects of β-thujaplicin analogs.

Organic Bimolecular Chemistry

2012

A direct route to analogs of the naturally occurring tropolone β-thujaplicin has been developed in just four steps from furan. Using this method, a series of derivatives were synthesized and evaluated. Several of these compounds demonstrated very high levels of potency against bacterial and fungal pathogens with good selectivity over mammalian cells.

View more

Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.

Drug Metabolism & Disposition

2012

Propargyl-linked antifolates that target dihydrofolate reductase are potent inhibitors of several species of pathogenic bacteria and fungi. This novel class of antifolates possesses a relatively uncommon acetylenic linker designed to span a narrow passage in the enzyme active site and join two larger functional domains.

View more

Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes

PloS One

2012

Hospital- and community-acquired, complicated skin and soft tissue infections, often attributed to Staphylococcus aureus and Streptococcus pyogenes, present a significant health burden that is associated with increased health care costs and mortality. As these two species are difficult to discern on diagnosis and are associated with differential profiles of drug resistance, the development of an efficacious antibacterial agent that targets both organisms is a high priority.

View more

Show All +